Newsroom

Sputnik V vaccine elicits high IGG antibodies and neutralizing antibodies titers, a study in Argentina published in international Cell Reports Medicine journal shows

Moscow, July 12, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), investor in the Russian Sputnik V vaccine against coronavirus, today announced results of a study in Argentina on vaccine’s IgG anti-spike titers and neutralizing capacity in non-infected and previously infected persons among healthcare workers.

The study has been published in an international peer-reviewed, open access Cell Reports Medicine journal: https://www.sciencedirect.com/science/article/pii/S2666379121002081

The research evaluates SARS-CoV-2-specific antibody responses after vaccination of 288 healthcare workers with Sputnik V in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses among non-infected and previously infected individuals.

There were 39 authors of the study including scientists Andres H. Rossi, Diego S. Ojeda, Augusto Varese, Lautaro Sanchez, Maria M. Gonzalez Lopez Ledesma, Ignacio Mazzitelli, and others. Among key findings in the article they note that the first dose of Sputnik V induced strong immune response in 94% of individuals previously not infected with COVID. It is also noted that there is no evident benefit of using a second dose in previously infected individuals. In authors’ opinion, vaccination with only the first component of Sputnik V (Sputnik Light vaccine) is sufficient to protect previously infected individuals.

To date, Sputnik V has been registered in 67 countries globally with a total population of over 3.5 billion people. The real world data obtained during the vaccination of the population in a number of countries, including Mexico, Argentina, Serbia, Bahrain, San Marino, Hungary, UAE and others, demonstrates that Sputnik V is one of the safest and most effective vaccines against coronavirus.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), commented:

“The piece published by experts from Argentina in Cell Reports Medicine journal is yet another example of a set of strong and positive data on real-world use of Sputnik V vaccine. It provides high-level protection for both previously non-infected individuals and those previously infected with COVID. Evidence is growing that Sputnik V is one of the safest and most effective vaccines against COVID in the world as confirmed by a set of data from regulators and scientific institutions in Latin America, Europe and the Middle East.”

***

Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling RUB2.1 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 1 mn people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at www.rdif.ru

For additional information contact:

Alexey Urazov
Russian Direct Investment Fund
Director for External Communications

Mobile: +7 915 312 76 65
E-mail: [email protected]

Andrew Leach / Maria Shiryaevskaya
Hudson Sandler

Tel: +44 (0) 20 7796 4133

Message has been successfully sent!

Thank you!
You have been subscribed